Sensome develops micro-sensor systems for medical devices which exploit impedance together with machine learning algorithms to reliably identify biological tissues.
Sensome, a France-based medtech device sensor spinout from École Polytechnique, received €4.6m ($5.4m) yesterday in a round featuring spinout-focused venture capital vehicle Paris-Saclay Seed Fund.
Venture capital firm Kurma Partners led the round, investing together with financial services firm BNP Paribas’s investment arm, BNP Paribas Développement, VC firm Idinvest and undisclosed additional investors.
Paris-Saclay Seed Fund launched in January 2017 with $53m in funding for spinouts of Paris-Saclay University.
Sensome develops micro-sensor systems for medical devices which exploit impedance and machine learning algorithms to reliably identify biological tissues.
The company’s first product, Clotild, applies the sensors with a guidewire to tackle ischemic stroke, which occurs when a clot obstructs a blood vessel in the brain.
Clotild works by instantly establishing the composition of the clot so that surgeons can promptly pursue the most appropriate emergency intervention.
Sensome will use the cash to conduct clinical trials on Clotild ahead of a planned launch in European markets. Additional funds will help Sensome hone in on other applications for the micro-sensor technology.
Sensome had already raised $5.4m in a Kurma-led seed round in July 2017 that featured Paris-Saclay Seed Fund, Idinvest and assorted angel investors.
Philippe Peltier, a partner at Kurma Partners, said: “We have been very impressed by Sensome’s progress over the past year.
“We share Sensome’s vision of connected medical devices to benefit an extended number of patients and are excited to be part of this upcoming revolution.”
